Supernus Pharmaceuticals Debt 2024

Supernus Pharmaceuticals Aktienanalyse

What does Supernus Pharmaceuticals do?

Supernus Pharmaceuticals Inc is an American company specializing in the development, manufacturing, and marketing of pharmaceuticals. The company was founded in 2005 and is headquartered in Rockville, Maryland. Initially, Supernus Pharmaceuticals focused on developing medications for neurological disorders such as epilepsy and ADHD. However, the company has since expanded into other areas of indication such as migraine and Parkinson's disease. The top products of Supernus Pharmaceuticals are the two epilepsy medications, Oxtellar XR and Trokendi XR, both based on a patented technology called "Troxerutin Enriched Osmotic Delivery System" (TREOS). This technology allows for timed release of the active ingredient, resulting in longer duration of action and improved tolerability. Both products are approved in the United States and have proven to be effective and well-tolerated. In addition to Oxtellar XR and Trokendi XR, Supernus Pharmaceuticals has launched other products on the market, including XADAGO for the treatment of Parkinson's disease and Qudexy XR for the treatment of migraine. The company also has a number of compounds in the pipeline currently in various stages of development. The business model of Supernus Pharmaceuticals is based on the development of proprietary technologies and the marketing of novel pharmaceuticals. The company works closely with industry and scientific partners to find innovative solutions to medical challenges. For Supernus Pharmaceuticals, quality is a central component of its business model. The company adheres to strict regulatory requirements and employs modern manufacturing techniques to ensure the highest standards in pharmaceutical production. Additionally, the company maintains close relationships with healthcare providers and patient organizations to ensure that its products meet the needs of patients. Supernus Pharmaceuticals also pursues a robust growth strategy based on exploring new markets and expanding its product portfolio. The company aims to expand its pipeline and develop new technologies to improve the treatment of neurological disorders and promote patient health worldwide. Overall, Supernus Pharmaceuticals is an innovative company distinguished by its commitment to quality and focus on novel solutions in the pharmaceutical industry. The company has established itself as a leading provider of medications for neurological disorders and strives to expand its position in this growing market. Supernus Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Supernus Pharmaceuticals's Debt Structure

Supernus Pharmaceuticals's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Supernus Pharmaceuticals's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Supernus Pharmaceuticals’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Supernus Pharmaceuticals’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Supernus Pharmaceuticals stock

What is the debt of Supernus Pharmaceuticals this year?

Supernus Pharmaceuticals has a debt level of -75.05 USD this year.

What was the debt of Supernus Pharmaceuticals compared to the previous year?

The debt of Supernus Pharmaceuticals has increased by -124.3% compared to the previous year dropped.

What are the consequences of high debt for investors in Supernus Pharmaceuticals?

High debt can pose a risk for investors of Supernus Pharmaceuticals, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Supernus Pharmaceuticals?

Low debt means that Supernus Pharmaceuticals has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Supernus Pharmaceuticals affect the company?

An increase in debt of Supernus Pharmaceuticals can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Supernus Pharmaceuticals affect the company?

A reduction in debt of Supernus Pharmaceuticals can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Supernus Pharmaceuticals?

Some factors that can influence the debt of Supernus Pharmaceuticals include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Supernus Pharmaceuticals so important for investors?

The debts of Supernus Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Supernus Pharmaceuticals take to change the debt?

To change the debt, Supernus Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Supernus Pharmaceuticals pay?

Over the past 12 months, Supernus Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Supernus Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Supernus Pharmaceuticals?

The current dividend yield of Supernus Pharmaceuticals is .

When does Supernus Pharmaceuticals pay dividends?

Supernus Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Supernus Pharmaceuticals?

Supernus Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Supernus Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Supernus Pharmaceuticals located?

Supernus Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Supernus Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Supernus Pharmaceuticals from 8/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/24/2024.

When did Supernus Pharmaceuticals pay the last dividend?

The last dividend was paid out on 8/24/2024.

What was the dividend of Supernus Pharmaceuticals in the year 2023?

In the year 2023, Supernus Pharmaceuticals distributed 0 USD as dividends.

In which currency does Supernus Pharmaceuticals pay out the dividend?

The dividends of Supernus Pharmaceuticals are distributed in USD.